LEVOFLOXACIN IN 5% DEXTROSE INJECTION SOLUTION

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

LEVOFLOXACIN

Disponible des:

STERIMAX INC

Codi ATC:

J01MA12

Designació comuna internacional (DCI):

LEVOFLOXACIN

Dosis:

5MG

formulario farmacéutico:

SOLUTION

Composición:

LEVOFLOXACIN 5MG

Vía de administración:

INTRAVENOUS

Unidades en paquete:

100ML/250ML

tipo de receta:

Prescription

Área terapéutica:

QUINOLONES

Resumen del producto:

Active ingredient group (AIG) number: 0131663001; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2016-12-22

Fitxa tècnica

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
LEVOFLOXACIN IN 5% DEXTROSE INJECTION
Levofloxacin
5 mg / mL Sterile solution for intravenous infusion
Antibacterial Agent
J01MA12 Levofloxacin
Submission Control Number: 270610
SteriMax Inc.
2770 Portland Drive
Oakville, ON
L6H 6R4
Date of Initial Authorization:
December 22, 2016
Date of Revision:
May 16, 2023
_LEVOFLOXACIN IN 5% DEXTROSE INJECTION Page 2 of 75_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
05/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
6
1.2
Geriatrics
...................................................................................................................
6
2
CONTRAINDICATIONS
.................................................................................................
6
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 6
4
DOSAGE AND ADMINISTRATION
.................................................................................
7
4.1
Dosing Considerations
..............................................................................................
7
4.2
Recommended Dose and Dosage Adjustment
......................................................... 7
4.4
Administration
..........................................................................................................
9
4.